Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
Public ClinicalTrials.gov record NCT00737243. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of Chemotherapy Treatment Based on Molecular Profiling Diagnosis for Patients With Carcinoma of Unknown Primary Site
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a non-randomized Phase II study. Patients determined at initial diagnosis to have a carcinoma of unknown primary site (CUP) will have their treatment selected with the use of a molecular profiling assay. The assay will be performed on paraffin-embedded tumor tissue from a biopsy specimen. Patients given specific diagnoses (e.g., lung, pancreas, colon, breast, renal cell, prostate and ovarian cancer) will receive treatment regimens of proven activity. If no specific diagnosis is made with the molecular profiling assay, empiric chemotherapy with paclitaxel, carboplatin, bevacizumab and erlotinib will be administered.
Study identification
- NCT ID
- NCT00737243
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 289 participants
Conditions and interventions
Conditions
Interventions
- Paclitaxel Drug
- Carboplatin Drug
- Bevacizumab Drug
- Erlotinib Drug
- Treatment determined by physician Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2008 (Type not available)
- Primary completion
- Nov 2012 (Actual)
- Completion
- Dec 2012 (Actual)
- Last update posted
- Aug 17, 2016
2008 – 2012
United States locations
- U.S. sites
- 21
- U.S. states
- 16
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Oncology Specialties (Clearview Cancer Institute) | Huntsville | Alabama | 35805 | — |
| Florida Cancer Specialists | Fort Myers | Florida | 33901 | — |
| Integrated Community Oncology Network | Jacksonville | Florida | 32256 | — |
| Watson Clinic Center for Cancer Care and Research | Lakeland | Florida | 33805 | — |
| Florida Hospital Cancer Institute | Orlando | Florida | 32804 | — |
| Northeast Georgia Medical Center | Gainesville | Georgia | 30501 | — |
| Wellstar Cancer Research | Marietta | Georgia | 30060 | — |
| Oncology Hematology Associates of SW Indiana | Evansville | Indiana | 47714 | — |
| Baptist Hospital East | Louisville | Kentucky | 40207 | — |
| Hematology Oncology Clinic, LLP | Baton Rouge | Louisiana | 70809 | — |
| Center for Cancer and Blood Disorders | Bethesda | Maryland | 20817 | — |
| Grand Rapids Clinical Oncology Program | Grand Rapids | Michigan | 49503 | — |
| Jackson Oncology Associates | Jackson | Mississippi | 39202 | — |
| Nebraska Methodist Cancer Center | Omaha | Nebraska | 68114 | — |
| Hematology Oncology Associates of Northern NJ | Morristown | New Jersey | 07960 | — |
| Oncology Hematology Care | Cincinnati | Ohio | 45242 | — |
| Spartanburg Regional Medical Center | Spartanburg | South Carolina | 29303 | — |
| Chattanooga Oncology Hematology Associates | Chattanooga | Tennessee | 37404 | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37023 | — |
| Center for Cancer and Blood Disorders | Fort Worth | Texas | 76104 | — |
| Virginia Cancer Institute | Richmond | Virginia | 23235 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00737243, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 17, 2016 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00737243 live on ClinicalTrials.gov.